Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
NCT00696332 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to assess the efficacy, tolerability and safety of oral administration of talampanel compared to a placebo in subjects with ALS.
Conditions Studied
Interventions
- OTHER placebo
- DRUG Talampanel
Study Locations (20)
Other
- Academic Hospital University of Leuven - ALS dept — Leuven
- C.H.U. La Timone - Service de Neurologie — Marseille
- C.H.U. de Montpellier - Hopital Gui de Chauliac - Service des Explorations Neurologiques — Montpellier
- Hopital La Pitie Salpetriere - Federation de Neurologie — Paris
- Universitaetsklinik Berlin-Charite, Campus Virchow Klinikum, Neurologische Klinik — Berlin
- Berufsgenossenschaftliche Klinik Bergmannsheil, Neurologische Klinik — Bochum
- Universitaet Ulm — Ulm
- Semmelweis University, Department of Neurology — Budapest
- Sourasky MC -EMG Unit — Tel Aviv
- Fondazione "S.Maugeri" Clinica della Riabilitazione IRCCS-Istituto Scientifico di Lissone — Lissone (MI)
New York
- Columbia University - Neurology Institute — New York
- SUNY Upstate Medical University — Syracuse
California
- CA Medical Center for Movement Disorders-Forbes Norris MDA/ALS Research Center — San Francisco
Kansas
- University of Kansas Medical Center - Dept of Neurology — Kansas City
Maryland
- Johns Hopkins OPC - Meyer Bldg — Baltimore
Massachusetts
- Massachusetts General Hospital-Neurology Clinical Trials Unit — Charlestown
Minnesota
- Mayo Clinic — Rochester
British Columbia
- ALS Centre — Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 559 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00696332
The ClinicalTrials.gov registry entry for NCT00696332 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 559 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 103 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with ALS appearing as the primary indexed condition, and to 2 interventions — of which placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00696332 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Other, New York, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00696332 about?
NCT00696332 is a clinical study titled "Talampanel for Amyotrophic Lateral Sclerosis (ALS)". The purpose of this study is to assess the efficacy, tolerability and safety of oral administration of talampanel compared to a placebo in subjects with ALS.
What is the current status of trial NCT00696332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 559 participants. The study started on 2008-09. Estimated completion is 2010-05.
What conditions does trial NCT00696332 study?
This clinical trial studies the following conditions: ALS. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00696332?
The interventions under investigation include: placebo (OTHER), Talampanel (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00696332?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 103 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00696332 being conducted?
This trial has 20 study locations across California, Kansas, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.